Does Plaquenil Cause Weight Gain?
No, Plaquenil (hydroxychloroquine) does not cause weight gain in patients with rheumatoid arthritis or lupus. In fact, hydroxychloroquine may have beneficial metabolic effects including improved glycemic control, which could theoretically support weight management rather than promote weight gain.
Evidence Against Weight Gain with Hydroxychloroquine
The provided evidence focuses extensively on glucocorticoid-related weight gain but does not identify hydroxychloroquine as a medication associated with weight gain 1. When discussing medications that cause weight gain in rheumatic disease patients, the literature specifically highlights:
- Glucocorticoids (prednisone/prednisolone) are the primary culprits, with weight gain being the most commonly reported side effect by patients with RA and lupus 1
- Antipsychotics, antiepileptics, and certain hormonal contraceptives are listed as weight-gain-associated medications, but hydroxychloroquine is notably absent from these lists 2
Metabolic Benefits of Hydroxychloroquine
Hydroxychloroquine actually demonstrates favorable metabolic effects that would work against weight gain:
- Lower fasting glucose levels were observed in both SLE and RA patients taking hydroxychloroquine compared to non-users (SLE: 85.9 vs 89.3 mg/dl, p=0.04; RA: 82.5 vs 86.6 mg/dl, p=0.05) 3
- Improved insulin sensitivity was demonstrated in women with SLE taking hydroxychloroquine, with lower HOMA-IR scores (0.97 vs 1.12, p=0.09) 3
- Reduced risk of type 2 diabetes has been reported with both hydroxychloroquine and chloroquine use 4
These metabolic improvements suggest hydroxychloroquine may actually help with glycemic control and potentially support weight management rather than promote weight gain 3.
Long-Term Safety Profile
The long-term safety data for hydroxychloroquine does not identify weight gain as a significant adverse effect:
- Primary reasons for discontinuation in RA patients were inefficacy (54% discontinued by 24 months), not weight-related side effects 5
- Documented adverse effects focus on retinopathy (rare, subclinical in only 2 of 108 patients), gastrointestinal symptoms, and dermatological reactions—not weight gain 6, 4
- SLE patients maintain treatment longer (only 24% discontinued by 24 months), suggesting good tolerability without significant weight-related concerns 5
Clinical Implications
If a patient on Plaquenil reports weight gain, investigate alternative causes:
- Concomitant glucocorticoid use is the most likely culprit, as prednisone causes weight gain ranging from 1.6-5 kg over months to years, even at low doses (5-10 mg) 1, 7
- Disease activity changes in RA or lupus may affect mobility and metabolism 4
- Other medications including antipsychotics, gabapentin, pregabalin, valproic acid, or medroxyprogesterone acetate should be reviewed 2
- Lifestyle factors and reduced physical activity due to joint symptoms 4
Important Caveat
The cardiovascular safety profile of hydroxychloroquine requires consideration in specific populations. In older RA patients (≥65 years) with a history of heart failure, hydroxychloroquine showed increased risks of MACE, cardiovascular mortality, and hospitalized heart failure compared to methotrexate 8. However, this cardiovascular concern is unrelated to weight gain and represents a separate safety consideration for patient selection.
Reassure patients that weight gain is not an expected side effect of Plaquenil therapy and focus monitoring on documented risks including retinal toxicity (requiring regular ophthalmologic examination) rather than weight changes 4, 6.